Abstract
The role of A1 and A3 receptors is discussed based on data almost exclusively obtained in the hippocampus. This brain area, where A1 receptor expression predominates, has been a matter of intensive research in the adenosine field. Interestingly, in the last decade, the relevance of the much less expressed adenosine receptor in the hippocampus, the A2A receptor, has been put forward. These two high affinity receptors operate as effective regulators of a number of neurotransmitters and/or neuromodulators, through modulation of their release, action, or even inactivation. Therefore, A1 and A2A receptors constitute a must in the discussion about adenosine receptors in the hippocampus, and consequently, about the potential implications of their pharmacological manipulation and drug targeting.
Keywords: Adenosine receptors, brain-derived neurotrophic factor, cannabinoids, γ-aminobutyric acid, glutamate, hippocampus, neuroprotection, vasoactive intestinal peptide, Adenosine receptors, brain-derived neurotrophic factor, cannabinoids, aminobutyric acid, glutamate, hippocampus, neuroprotection, vasoactive intestinal peptide, ACh, AMPA
CNS & Neurological Disorders - Drug Targets
Title:From A1 to A3 en passant Through A2A Receptors in the Hippocampus: Pharmacological Implications
Volume: 11 Issue: 6
Author(s): Ana M. Sebastiao, Filipa F. Ribeiro and Joaquim A. Ribeiro
Affiliation:
Keywords: Adenosine receptors, brain-derived neurotrophic factor, cannabinoids, γ-aminobutyric acid, glutamate, hippocampus, neuroprotection, vasoactive intestinal peptide, Adenosine receptors, brain-derived neurotrophic factor, cannabinoids, aminobutyric acid, glutamate, hippocampus, neuroprotection, vasoactive intestinal peptide, ACh, AMPA
Abstract: The role of A1 and A3 receptors is discussed based on data almost exclusively obtained in the hippocampus. This brain area, where A1 receptor expression predominates, has been a matter of intensive research in the adenosine field. Interestingly, in the last decade, the relevance of the much less expressed adenosine receptor in the hippocampus, the A2A receptor, has been put forward. These two high affinity receptors operate as effective regulators of a number of neurotransmitters and/or neuromodulators, through modulation of their release, action, or even inactivation. Therefore, A1 and A2A receptors constitute a must in the discussion about adenosine receptors in the hippocampus, and consequently, about the potential implications of their pharmacological manipulation and drug targeting.
Export Options
About this article
Cite this article as:
M. Sebastiao Ana, F. Ribeiro Filipa and A. Ribeiro Joaquim, From A1 to A3 en passant Through A2A Receptors in the Hippocampus: Pharmacological Implications, CNS & Neurological Disorders - Drug Targets 2012; 11 (6) . https://dx.doi.org/10.2174/187152712803581074
DOI https://dx.doi.org/10.2174/187152712803581074 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A panoramic view of chronic liver diseases and natural remedies reported in Traditional Persian Medicine
Current Pharmaceutical Design Adenosine Neuromodulation and Traumatic Brain Injury
Current Neuropharmacology A Review on the Phytochemicals, Ethnomedicine Uses and Pharmacology of Ficus Species
Current Traditional Medicine Update on Diagnostic and Treatment of Uncomplicated and Complicated Malaria in Adults and Selected Vulnerable Populations
Infectious Disorders - Drug Targets Natural Products Based Ayurvedic Formulations: Chemical Cons tituents and Treatment in Neurodegenerative Disordersǂ
Mini-Reviews in Organic Chemistry Phytochemical Analysis with Antioxidant and Cytotoxicity Studies of the Bioactive Principles from Zanthoxylum capense (Small Knobwood)
Anti-Cancer Agents in Medicinal Chemistry Early Intervention in Psychosis: Rationale, Results and Implications for Treatment of Adolescents at Risk
Adolescent Psychiatry Medicinal Chemistry and Therapeutic Potential of Agonists, Antagonists and Allosteric Modulators of A1 Adenosine Receptor: Current Status and Perspectives
Current Pharmaceutical Design Suicidality and Cannabidiol: Opportunities and Challenges
Current Neuropharmacology Pharmacological Inhibition of Voltage-gated Ca<sup>2+</sup> Channels for Chronic Pain Relief
Current Neuropharmacology Extract of <i>Moringa concanensis</i> Nimmo Leaves Ameliorates Hyperglycemia and Oxidative Stress, and Improves β-cell Function in Alloxan Monohydrate Induced Diabetic Rats
Current Bioactive Compounds Targeting Glutamatergic Signaling for the Development of Novel Therapeutics for Mood Disorders
Current Pharmaceutical Design Multiple Roles for Glycogen Synthase Kinase-3 as a Drug Target in Alzheimers Disease
Current Drug Targets A Magnetic Resonance Spectroscopy Study of Lovastatin for Treating Bipolar Mood Disorder: A 4-Week Randomized Double-Blind, Placebo- Controlled Clinical Trial
Recent Patents on Inflammation & Allergy Drug Discovery Use of Antiepileptic Drugs for Hyperkinetic Movement Disorders
Current Neuropharmacology Glial Cells – The Key Elements of Alzheimer´s Disease
Current Alzheimer Research Conference Report: 10th International Summer School of Neurology: Celebrating a Decade of Success: 5th July, 2015 – 9th July, 2015 | Eforie Nord, Romania
CNS & Neurological Disorders - Drug Targets From Cannabis to Cannabidiol to Treat Epilepsy, Where Are We?
Current Pharmaceutical Design Food Selectivity, Gastrointestinal Symptoms and Urine Organic Acids in Autism Spectrum Disorder: A Pilot Study
Current Nutrition & Food Science 3D Printing Technology in Pharmaceutical Manufacturing and Drug Delivery Application
Current Pharmaceutical Design